Rod McNeil; Reviewed by Dr David S. Boyer, Prof. Ramin Tadayoni, Dr Jeffrey S. Heier and Dr Paul Hahn

Although the majority of patients experience benefit with brolucizumab for the treatment of nAMD without severe adverse events, the risk of retinal vasculitis and/or retinal vascular occlusion needs to be balanced with potential benefits.